FerroSens and Photonamic Announce Approval and Launch of FID*screen*™ for Non-Invasive Iron Deficiency Testing

Closer strategic collaboration for launch of FID*screen*™, beginning with pediatric care in Germany in Q4 2026

MUNICH and PINNEBERG, Germany, 9th September 2026 – FerroSens GmbH ("FerroSens") and photonamic GmbH & Co. KG ("photonamic") today announced that FID*screen*™, an innovative non-invasive diagnostic device for iron deficiency measurement, has received CE certification under the EU Medical Device Regulation (MDR). The approval represents a major milestone for both companies and paves the way for the commercial launch of the technology.

After several years of extensive research and development, clinical studies on more than 1,000 participants showed the high reliability and accuracy of FID*screen*´s non-invasive measurement technique. FerroSens and photonamic both have expertise in fluorescence-based technologies and will strengthen their collaboration further to bring FID*screen*™ to healthcare professionals and patients, with the first launch planned in Germany during the fourth quarter of 2026.

The initial market focus will be on pediatric care, where the need for simple and accessible iron deficiency screening remains significant. Iron deficiency is one of the most common nutritional deficiencies worldwide, and early detection and treatment are particularly important in infants and children.

Unlike conventional diagnostic methods that require blood sampling and laboratory analysis, FID*screen*™ enables healthcare professionals to perform a rapid, non-invasive measurement directly at the point of care. The examination is conducted through a simple optical scan on the lower lip, eliminating the need for blood collection and providing results within minutes.

For infants and children, the non-invasive nature of this test offers a particularly important advantage. The avoidance of blood drawing can reduce discomfort and anxiety for both children and their parents while supporting broader access to routine iron deficiency screening.

"The CE certification of FIDscreen is a major achievement for FerroSens and photonamic and reflects years of dedicated research and development," said Dr. Ulrich Kosciessa,

CEO of photonamic. *"Our vision has always been to provide healthcare professionals with a fast, reliable and truly non-invasive solution for detecting iron deficiency,"* added Dr. Christian Homann, Founder and CEO of FerroSens.

About FID*screen*™

FID*screen*™ is a CE-certified medical device developed by FerroSens for the non-invasive diagnosis of iron deficiency through the determination of the zinc protoporphyrin IX / heme ratio (ZnPP/heme), an established marker for iron deficiency. ZnPP/heme detects iron deficiency before the onset of anemia and is more stable in case of acute infections than ferritin. Measurements are performed through an optical method (fluorescence spectroscopy) on the lower lip and provide results within minutes at the point of care, without blood sampling.

About FerroSens GmbH

FerroSens GmbH is a Munich-based medical technology company specializing in optical, non-invasive diagnostic solutions. The company was founded in 2017 as a spin-off of the Laser Research Laboratory, an institute of the LIFE Center, at the LMU Klinikum Munich. The company's mission is based on the WHO's proclaimed research priority to develop a cost-effective, portable, reliable instrument to measure the iron parameter Zinc Protoporphyrin.

About photonamic GmbH & Co. KG

photonamic is a German-based life-science company focused on the development and commercialization of innovative healthcare solutions, including 5-ALA-based technologies such as Gliolan® for fluorescence-guided resection of glioblastoma. As a member of the SBI Group, photonamic and its affiliated companies in the US and Japan are diligently extending the development activities within fluorescence technology. Since 2021, photonamic has been majority shareholder of FerroSens.